

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 March 2025 (06.03.2025)



(10) International Publication Number
WO 2025/049662 A1

(51) International Patent Classification:

C07D 471/04 (2006.01) A61P 25/00 (2006.01)
A61K 31/437 (2006.01) A61P 25/14 (2006.01)
A61P 3/00 (2006.01)

(21) International Application Number:

PCT/US2024/044308

(22) International Filing Date:

29 August 2024 (29.08.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/535,435 30 August 2023 (30.08.2023) US

(71) Applicant: AGIOS PHARMACEUTICALS, INC.
[US/US]; 88 Sidney Street, Cambridge, MA 02139 (US).

(72) Inventors: DE PASCALIS, Lucrezia; c/o Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, MA 02139 (US). LIU, Peng; c/o Agios Pharmaceuticals, Inc., 88 Sidney Street, Cambridge, MA 02139 (US). SHOOK, Brian, C.; 199 Mohawk Path, Holliston, MA 01746 (US).

(74) Agent: DEGRAZIA, Michael, J. et al.; McCarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: 4-PYRAZOLO[1,5-A]PYRIDIN-2-YL-4,5,6,7-TETRAHYDRO-1H-IMIDAZO[4,5-C]PYRIDINE DERIVATIVES AS MUTANT PAH PROTEIN STABILIZERS FOR THE TREATMENT OF PHENYLKETONURIA



(57) Abstract: The disclosure is directed to 4-pyrazolo[1,5-a]pyridin-2-yl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine derivatives of formula (I) and pharmaceutically acceptable salts thereof, that stabilize phenylalanine hydroxylase (PAH) mutations, pharmaceutical compositions comprising those compounds, and methods of using those compounds in methods for stabilizing a mutant PAH protein or reducing blood phenylalanine concentration in a subject suffering from phenylketonuria. In some embodiments, the mutant PAH protein contains at least one R408W, R261Q, R243Q, Y414C, L48S, A403V, I65T, R241C, L348V, R408Q, or V388M mutation. In other embodiments, the mutant PAH protein contains at least one R408W, Y414C, I65T, F39L, R408Q, L348V, R261Q, A300S, or L48S mutation.

WO 2025/049662 A1